GM 6001 - ≥98%, high purity , CAS No.142880-36-2, Inhibitor of ADAM10;Inhibitor of ADAM12;Inhibitor of ADAM17;Inhibitor of ADAM9;Inhibitor of MMP1;Inhibitor of MMP12;Inhibitor of MMP13;Inhibitor of MMP14;Inhibitor of MMP15;Inhibitor of MMP16;Inhibitor of MMP17;Inhibitor of MMP2;Inhibitor of MMP26;Inhibit

Item Number

G274767

• Synonyms: (2R)-N'-hydroxy-N-[(2S)-3-(1H-indol-3-yl)-1-(methylamino)-1-oxopropan-2-yl]-2-(2-methylpropyl)butanediamide | BDBM234334 | CS-0011196 | NDGA;Masoprocol | SMR000054918 | (R)-N1-((S)-3-(1H-Indol-3-yl)-1-(methylamino)-1-oxopropan-2-yl)-N4-hydroxy-2-isobutyl
• Specifications & Purity: Moligand™, ≥98%
• Biochemical and Physiological Mechanisms: GM6001 promotes cardiovascular and hepatocellular function. Inhibits a wide variety of matrix metalloproteases with Kis in the nanomolar range. Active in a number of animal models of diseases where matrix metalloproteases are thought to be involved.
• Storage Temp: Store at -20°C
• Shipped In: Ice chest + Ice pads
• Grade: Moligand™
• Action Type: INHIBITOR
• Mechanism of action: Inhibitor of ADAM10;Inhibitor of ADAM12;Inhibitor of ADAM17;Inhibitor of ADAM9;Inhibitor of MMP1;Inhibitor of MMP12;Inhibitor of MMP13;Inhibitor of MMP14;Inhibitor of MMP15;Inhibitor of MMP16;Inhibitor of MMP17;Inhibitor of MMP2;Inhibitor of MMP26;Inhibit
• Note: Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

Product Description

Application:
(R)-N4-Hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide has been used: To study its effect on the profiling of active aggrecanases and their specific aggrecan degradation fragments. To study the involvement of autocrine EGF (epidermal growth factor) receptor activation in the regulation of the morphogenetic process, using human umbilical vein endothelial cells. To study the effect of GM6001 blockade on the expression of angiotensin II, the interstitial collagenases and soluble elastin fragments in explant culture supernatants.